AOD-9604

AOD-9604 is a peptide fragment derived from the C-terminal region (amino acids 176-191) of human growth hormone. It is designed to mimic the fat-reducing effects of growth hormone without the broader anabolic effects associated with full-length hormone administration. Initially developed to explore potential treatments for obesity, AOD-9604 has been the subject of preclinical and early clinical research aimed at understanding its metabolic actions.

The peptide was first synthesized and characterized in the early 2000s, with phase IIa trials underway by 2002 to evaluate its efficacy in weight management. Its structural modification allows it to act selectively on lipid metabolism pathways, distinguishing it from traditional growth hormone therapies.

Researchers study AOD-9604 primarily for its potential to modulate fat metabolism and promote tissue repair through growth hormone secretagogue activity. It activates insulin-like growth factor-1 (IGF-1) signaling pathways and stimulates satellite cell repair mechanisms, which may have implications beyond weight loss, such as tissue regeneration and metabolic regulation.

As a research chemical, AOD-9604 remains under investigation in preclinical and limited clinical settings. It is not approved by regulatory agencies such as the FDA for therapeutic use and is primarily utilized in laboratory research contexts to further elucidate its biological effects and therapeutic potential.

Research on AOD-9604 spans metabolic and orthopaedic contexts. The 2004 study "AOD-9604 Metabolic." reported that Metabolic was developing AOD-9604 for potential obesity treatment, with phase IIa trials underway by early 2002, indicating an early clinical research interest in its fat metabolism effects.

The 2026 review "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions." highlights AOD-9604 among growth hormone secretagogues that activate IGF-1 signaling and satellite cell repair, emphasizing its mechanistic role in tissue regeneration and metabolic regulation within musculoskeletal research. The review notes promising preclinical findings but underscores a current lack of clinical trials.

The 2013 study "AOD-9604 does not influence the WADA hGH isoform immunoassay." addresses detection concerns, concluding that AOD-9604 does not interfere with growth hormone isoform immunoassays used in doping control, which is relevant for research into its biological activity and regulatory considerations.

Research literature on AOD-9604 includes limited data on dosing protocols, primarily within early-phase clinical trials and preclinical studies. Specific dose ranges are not well established, and reported protocols vary depending on the research model and study design.

In the context of metabolic research, some phase IIa trials have explored dosing schedules to evaluate safety and efficacy, but comprehensive dosing guidelines remain unavailable. Researchers typically administer AOD-9604 in controlled laboratory settings, using doses tailored to the experimental objectives and species studied. Due to the lack of standardized dosing data, all use remains strictly within research parameters without clinical dosing recommendations.